Many clinical trials have reported kidney-related outcomes after the use of SGLT2 inhibitors.[8,9,16,17] At present, there is no systematic review on whether SGLT2 inhibitors can preserve renal function, reduce UACR, and decrease adverse effects in patients with T2DM and CKD. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.